MPI has now executed transfer of the last tranche of the Oncology Venture shares sold during May
Medical Prognosis Institute A/S (”MPI”) hereby announces that the last tranche of its holdings in Oncology Venture Sweden AB (”Oncology Venture”) is now transferred. As earlier announced MPI has as part of the merger capitalized it’s shareholding in Oncology Venture. The sale of the shares was announced in May 31, 2018. The last tranche of the sold shares (662,038) is now being transferred to the new owners. Please note that Peter Buhl Jensen will - as the CEO on behalf of MPI - be noted as the responsible person for the sale. For further information, please contact Ulla Hald Buhl,